Unknown

Dataset Information

0

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.


ABSTRACT: BACKGROUND AND OBJECTIVES:In patients with chronic noncancer pain, subcutaneous methylnaltrexone for opioid-induced constipation (OIC) was examined in a randomized controlled trial (RCT) followed by an open-label extension (OLE). This study examined the reproducibility of RCT findings by analyzing data from placebo-treated patients who crossed over to methylnaltrexone. METHODS:Adults with less than 3 weekly rescue-free bowel movements (RFBMs), taking 50 mg or more of an oral morphine equivalent per day, were randomized to receive methylnaltrexone 12 mg or placebo for 4 weeks, followed by open-label methylnaltrexone 12 mg as needed for 8 weeks. RESULTS:A total of 134 placebo-treated patients (median morphine equivalent dose, 150 mg/d; mean of 1.1 RFBM per week) crossed over to methylnaltrexone in OLE. During the RCT, 9.7% of placebo-treated patients experienced an RFBM within 4 hours of first dose and 9.0% of all placebo injections resulted in an RFBM within 4 hours compared with 45.9% and 34.5%, respectively, with methylnaltrexone treatment in the OLE. When expressed as percentage of patients experiencing 3 or more RFBMs per week and a 1-RFBM increase over baseline, weekly values ranged from 35% to 40% during placebo treatment; at week 5 of OLE methylnaltrexone, this percentage increased to more than 70% and remained relatively stable throughout the OLE. The most common adverse events during methylnaltrexone treatment were abdominal pain (9.7% vs 1.5% for placebo) and nausea (5.2% vs 6.7%). CONCLUSIONS:Findings during placebo treatment further establish the profile of OIC and support that little or no gastrointestinal tolerance develops across time. Findings under open-label conditions established the reproducibility and durability of methylnaltrexone for OIC.

SUBMITTER: Viscusi ER 

PROVIDER: S-EPMC4684250 | biostudies-literature | 2016 Jan-Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.

Viscusi Eugene R ER   Barrett Andrew C AC   Paterson Craig C   Forbes William P WP  

Regional anesthesia and pain medicine 20160101 1


<h4>Background and objectives</h4>In patients with chronic noncancer pain, subcutaneous methylnaltrexone for opioid-induced constipation (OIC) was examined in a randomized controlled trial (RCT) followed by an open-label extension (OLE). This study examined the reproducibility of RCT findings by analyzing data from placebo-treated patients who crossed over to methylnaltrexone.<h4>Methods</h4>Adults with less than 3 weekly rescue-free bowel movements (RFBMs), taking 50 mg or more of an oral morph  ...[more]

Similar Datasets

| S-EPMC6307492 | biostudies-literature
| S-EPMC5914419 | biostudies-literature
| S-EPMC6095122 | biostudies-literature
| S-EPMC4634837 | biostudies-literature
| S-EPMC4424379 | biostudies-literature
| S-EPMC6205130 | biostudies-literature
| S-EPMC7170446 | biostudies-literature
| S-EPMC8485099 | biostudies-literature
| S-EPMC5914456 | biostudies-literature
| S-EPMC4282321 | biostudies-literature